United States Gastrointestinal Therapeutics Market Trends | Biologics, Personalized Medicine & Regional Growth Forecast 2033

Gastrointestinal Therapeutics Market is estimated to grow at a CAGR of 6.42% during the forecast period (2024-2031)

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/gastrointestinal-therapeutics-market?kb

United States: Recent Industry Developments

✅ November 2025: AbbVie launched a novel biologic therapy targeting moderate to severe Crohn's disease with enhanced efficacy and safety profiles.

✅ October 2025: The FDA approved a new oral small molecule drug for irritable bowel syndrome (IBS) with improved patient compliance.

✅ September 2025: Increased adoption of digital health tools to monitor and manage chronic gastrointestinal conditions remotely.

GCC: Recent Industry Developments

✅ November 2025: Gulf Pharmaceutical Industries introduced advanced therapeutics for ulcerative colitis, expanding access in the GCC market.

✅ October 2025: Collaborations between GCC health authorities and pharma companies aimed to improve early diagnosis and treatment of gastrointestinal cancers.

✅ September 2025: Investment in regional clinical trials accelerated the development of novel GI drugs tailored to the local population.

MENA: Recent Industry Developments

✅ November 2025: Local biotech firms partnered with global pharmaceutical companies to enhance treatment options for hepatitis and liver disorders.

✅ October 2025: Health ministries across MENA increased funding for public awareness campaigns focusing on digestive health and lifestyle management.

✅ September 2025: Expansion of specialty clinics providing multidisciplinary care for complex GI disorders, including motility and functional diseases.

Key Players:

Abbott, Allergan, Johnson & Johnson, Takeda, Novartis, Pfizer, Merck, F. Hoffmann-La Roche, Eli Lilly, AstraZeneca, Procter & Gamble, and Shire Pharmaceuticals

Latest M&A

1. Genmab acquired Merus N.V. for $8 billion, gaining access to bispecific antibody petosemtamab targeting cancers including GI cancers.​

2. Roche acquired 89bio for $3.5 billion, adding Phase III-ready FGF21 analog for metabolic liver diseases with GI implications.​

3. GSK acquired Boston Pharmaceuticals' late-stage FGF21 analog efimosfermin alfa for $2 billion, enhancing its nonalcoholic steatohepatitis (NASH) and GI disease pipeline.

Growth Forecast Projection:

The Global Gastrointestinal Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Gastrointestinal Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Latest Drugs and Product Launches

1. FDA approved sotorasib plus panitumumab for KRAS G12C-mutated metastatic colorectal cancer, improving progression-free survival significantly.​

2. Pembrolizumab combination also granted full FDA approval for HER2-positive gastric and gastroesophageal cancers.​

3. Retifanlimab received FDA approval for anal canal carcinoma, expanding immunotherapy options in GI oncology.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=gastrointestinal-therapeutics-market?kb

Key Segmentation:

By Product Category: (Branded, Generic), By Route of Administration (Oral, Parenteral, Others)

By Application: (Ulcerative Colitis, GI Bleeding, Laxatives, Irritable Bowel Syndrome, Peptic Ulcer Disease (PUD), Others)

By End User: (Hospitals, Clinics, Others)

By Distribution Channel: (Hospital Pharmacie, Retail Pharmacies, Online Pharmacies)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Gastrointestinal Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Gastrointestinal Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/gastrointestinal-therapeutics-market?kb

Clinical Trials and Project Hubs

1. Multiple Phase III clinical trials ongoing for therapies addressing Crohn's disease, ulcerative colitis, and metabolic liver diseases with GI co-morbidities.​

2. Emerging GI disease-focused research centers and biotech hubs in North America, Europe, and Asia-Pacific drive innovation in RNA therapeutics, biologics, and small molecules.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/gastrointestinal-therapeutics-market?kb

Latest Investments

1. Ironwood Pharmaceuticals announced new real-world data on linaclotide (Linzess) for pediatric IBS-C and functional constipation, suggesting ongoing investment in GI therapeutic efficacy and adoption.​

2. Significant R&D funding is focused on next-generation oral small molecules, biologics, biosimilars, and immunotherapy combinations targeting GI cancers and metabolic GI diseases.

Related Reports:

Personalized Medicine Market: https://www.datamintelligence.com/download-sample/personalized-medicine-market?kb

Biologics Outsourcing Market: https://www.datamintelligence.com/download-sample/biologics-outsourcing-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.